- Country: Thailand
- Summary: Ta-9950 Reg: Tha: Adverse Event Following Immunization/ Adverse Drug Reaction Surveillance Expert (54079-001)
- THT Ref No: 77010562
- Deadline: 11 Jan 2023
- Financier: Asian Development Bank (ADB)
- Purchaser Ownership: Government
- Tender Value: USD 40000
- Notice Type: Tender
- Document Ref. No.:
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Tender are invited for Ta-9950 Reg: Tha: Adverse Event Following Immunization/ Adverse Drug Reaction Surveillance Expert (54079-001)
Consultant Type : Individual
Selection Method : Individual Consultant Selection (Ics)
Selection Title : THA: Adverse Event Following Immunization/ Adverse Drug Reaction Surveillance Expert
Deadline of Submitting EOI : 11-Jan-2023 11:59 PM Manila local time - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINTa-9950 Reg: Tha: Adverse Event Following Immunization/ Adverse Drug Reaction Surveillance Expert (54079-001) - Thailand Tender
The ASIAN DEVELOPMENT BANK (ADB), a Government sector organization in Thailand, has announced a new tender for Ta-9950 Reg: Tha: Adverse Event Following Immunization/ Adverse Drug Reaction Surveillance Expert (54079-001). This tender is published on ThailandTenders under THT Ref No: 77010562 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-01-11.
The estimated tender value is USD 40000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
